Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT04100148




Registration number
NCT04100148
Ethics application status
Date submitted
20/09/2019
Date registered
24/09/2019
Date last updated
15/03/2024

Titles & IDs
Public title
SyncAV Post-Market Trial
Scientific title
SyncAV Post-Market Trial
Secondary ID [1] 0 0
ABT-CIP-10299
Universal Trial Number (UTN)
Trial acronym
SyncAV
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Congestive Heart Failure 0 0
Condition category
Condition code
Cardiovascular 0 0 0 0
Coronary heart disease
Cardiovascular 0 0 0 0
Other cardiovascular diseases

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Devices - SyncAV programmed ON
Treatment: Devices - Fixed AV delay

Experimental: SyncAV Arm - Treatment Arm

Active Comparator: Fixed AV Delay Arm - Control Arm


Treatment: Devices: SyncAV programmed ON
For those subjects randomized to SyncAV programmed ON, sites will measure QRS duration with the subject's intrinsic rhythm (pacing OFF), at BiV pacing nominal settings, with various SyncAV programmed offsets, and at LV first 30 ms, RV first 30 ms and LV-only pacing with optimal SyncAV offsets. The site will then program the subject's device using the SyncAV offset that provided the narrowest QRS duration.

Treatment: Devices: Fixed AV delay
For those subjects randomized to the fixed AV delay arm, sites will measure QRS duration with the subject's intrinsic rhythm (pacing OFF) and at BiV pacing nominal settings. Sites will then program the subject's device using BiV pacing nominal settings.
Intervention code [1] 0 0
Treatment: Devices
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Reduction in left ventricular end systolic volume (LVESV) between baseline and 12 months
Timepoint [1] 0 0
12 months following trial randomization
Secondary outcome [1] 0 0
Percentage of CRT Responders at 12 months
Timepoint [1] 0 0
12 months following trial randomization
Secondary outcome [2] 0 0
Reduction in LVESV in female subjects between baseline and 12 months
Timepoint [2] 0 0
12 months following trial randomization
Secondary outcome [3] 0 0
Percentage of female subjects classified as CRT Responders at 12 months
Timepoint [3] 0 0
12 months following trial randomization

Eligibility
Key inclusion criteria
1. Scheduled to receive a new CRT implant or an upgrade (Abbott CRT device and Abbott
Quadripolar LV lead) from an existing implantable cardioverter defibrillator/pacemaker
implant with no more than 10% RV pacing at the last device interrogation, no prior LV
lead placement, AND meet the following additional criteria:

1. Mild to severe heart failure despite optimal medical therapy for at least 3
months prior to signing consent. Optimal medical therapy is defined as maximal
tolerated dose of beta-blockers and a therapeutic dose of angiotensin-converting
enzyme inhibitor, angiotensin receptor blocker, or aldosterone antagonist

2. LVEF = 35% based on a prior standard of care echocardiogram

3. Left bundle branch block (LBBB) as documented on an ECG. Criteria for complete
LBBB should include,

i. QRS duration = 120 ms ii. QS or rS pattern in leads V1 iii. mid-QRS notching or
slurring in leads I, aVL, V5, and V6 iv. Absence of Q-wave in leads V5 and V6 d.
Intact AV conduction (PR interval = 280 ms on surface ECG)

2. At least 18 years old, or of legal age and willing and capable to give informed
consent specific to each country and national laws

3. Willing and able to comply with the prescribed follow-up tests and schedule of
evaluations
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Recent myocardial infarction or unstable angina within 40 days prior to signing
consent

2. Recent cardiac revascularization (angioplasty, stent or bypass graft) in the 4 weeks
prior to signing consent or planned within 3 months following consent

3. Cerebrovascular accident or transient ischemic attack in the 3 months prior to signing
consent

4. Any other therapeutic cardiovascular procedure (transcatheter aortic valve
replacement, MitraClip, cardiac surgery, left atrial appendage closure, patent foramen
ovale closure, or any ablation procedures) in the 3 months prior to signing consent

5. Permanent or persistent AF at the time of signing consent

6. Paroxysmal AF with at least one cardioversion within 60 days prior to signing consent

7. Prior CRT device implant

8. Prior His Bundle pacing implant or plan to have His Bundle pacing implant

9. Pregnant or breastfeeding at the time of signing consent

10. Incapacitated or unable to read or write

11. Undergone cardiac transplantation or have a classification of Status 1 for cardiac
transplantation or consideration for transplantation during the study follow-up period

12. Life expectancy < 12 months due to any condition

13. Unavailable for at least 12 months of follow-up visits

14. Enrolled in or intend to participate in a clinical drug and/or device study during
this clinical trial which could confound the results of this trial as determined by
Abbott

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Not Applicable
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
3/10/2019
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
31/12/2025
Actual
Sample size
Target
1400
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Warringal Private Hospital - Heidelberg
Recruitment postcode(s) [1] 0 0
- Heidelberg
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Arizona
Country [3] 0 0
United States of America
State/province [3] 0 0
California
Country [4] 0 0
United States of America
State/province [4] 0 0
Colorado
Country [5] 0 0
United States of America
State/province [5] 0 0
District of Columbia
Country [6] 0 0
United States of America
State/province [6] 0 0
Florida
Country [7] 0 0
United States of America
State/province [7] 0 0
Georgia
Country [8] 0 0
United States of America
State/province [8] 0 0
Iowa
Country [9] 0 0
United States of America
State/province [9] 0 0
Kentucky
Country [10] 0 0
United States of America
State/province [10] 0 0
Massachusetts
Country [11] 0 0
United States of America
State/province [11] 0 0
Michigan
Country [12] 0 0
United States of America
State/province [12] 0 0
Mississippi
Country [13] 0 0
United States of America
State/province [13] 0 0
Missouri
Country [14] 0 0
United States of America
State/province [14] 0 0
New Hampshire
Country [15] 0 0
United States of America
State/province [15] 0 0
New Jersey
Country [16] 0 0
United States of America
State/province [16] 0 0
New York
Country [17] 0 0
United States of America
State/province [17] 0 0
North Carolina
Country [18] 0 0
United States of America
State/province [18] 0 0
Ohio
Country [19] 0 0
United States of America
State/province [19] 0 0
Oklahoma
Country [20] 0 0
United States of America
State/province [20] 0 0
Pennsylvania
Country [21] 0 0
United States of America
State/province [21] 0 0
South Carolina
Country [22] 0 0
United States of America
State/province [22] 0 0
Texas
Country [23] 0 0
United States of America
State/province [23] 0 0
Virginia
Country [24] 0 0
Austria
State/province [24] 0 0
Styria
Country [25] 0 0
Belgium
State/province [25] 0 0
Brussels
Country [26] 0 0
Canada
State/province [26] 0 0
Alberta
Country [27] 0 0
Canada
State/province [27] 0 0
British Columbia
Country [28] 0 0
Canada
State/province [28] 0 0
Montreal
Country [29] 0 0
Canada
State/province [29] 0 0
Newfoundland and Labrador
Country [30] 0 0
Canada
State/province [30] 0 0
Nova Scotia
Country [31] 0 0
Canada
State/province [31] 0 0
Ontario
Country [32] 0 0
Canada
State/province [32] 0 0
Quebec
Country [33] 0 0
Canada
State/province [33] 0 0
Edmonton
Country [34] 0 0
China
State/province [34] 0 0
Heping
Country [35] 0 0
China
State/province [35] 0 0
Shaanxi
Country [36] 0 0
China
State/province [36] 0 0
Zhejiang
Country [37] 0 0
Colombia
State/province [37] 0 0
Antioq
Country [38] 0 0
Finland
State/province [38] 0 0
Helsinki
Country [39] 0 0
France
State/province [39] 0 0
AQT
Country [40] 0 0
France
State/province [40] 0 0
Ile-de-France
Country [41] 0 0
France
State/province [41] 0 0
Midi-Pyrenees
Country [42] 0 0
France
State/province [42] 0 0
Rennes
Country [43] 0 0
France
State/province [43] 0 0
Saint-Priest-En-Jarez
Country [44] 0 0
Germany
State/province [44] 0 0
Bad-wur
Country [45] 0 0
Germany
State/province [45] 0 0
Saxony
Country [46] 0 0
Germany
State/province [46] 0 0
Bad Nauheim
Country [47] 0 0
Germany
State/province [47] 0 0
Hannover
Country [48] 0 0
Hong Kong
State/province [48] 0 0
Hong Kong
Country [49] 0 0
India
State/province [49] 0 0
Andprad
Country [50] 0 0
India
State/province [50] 0 0
Gujarat
Country [51] 0 0
India
State/province [51] 0 0
Karnataka
Country [52] 0 0
India
State/province [52] 0 0
Gurgaon
Country [53] 0 0
India
State/province [53] 0 0
New Delhi
Country [54] 0 0
Italy
State/province [54] 0 0
Apulia
Country [55] 0 0
Italy
State/province [55] 0 0
Calabria
Country [56] 0 0
Italy
State/province [56] 0 0
Avellino
Country [57] 0 0
Japan
State/province [57] 0 0
Chiba
Country [58] 0 0
Japan
State/province [58] 0 0
Hyogo
Country [59] 0 0
Japan
State/province [59] 0 0
Kanagawa-Ken
Country [60] 0 0
Japan
State/province [60] 0 0
Kanagwa
Country [61] 0 0
Korea, Republic of
State/province [61] 0 0
Sudogwn
Country [62] 0 0
Korea, Republic of
State/province [62] 0 0
Daegu
Country [63] 0 0
Korea, Republic of
State/province [63] 0 0
Seoul
Country [64] 0 0
Netherlands
State/province [64] 0 0
Noord-h
Country [65] 0 0
Poland
State/province [65] 0 0
Lesrpld
Country [66] 0 0
Poland
State/province [66] 0 0
Poznan
Country [67] 0 0
Portugal
State/province [67] 0 0
Sntarem
Country [68] 0 0
Portugal
State/province [68] 0 0
Lisboa
Country [69] 0 0
Puerto Rico
State/province [69] 0 0
Ponce
Country [70] 0 0
Russian Federation
State/province [70] 0 0
Siberia
Country [71] 0 0
Saudi Arabia
State/province [71] 0 0
Makkah
Country [72] 0 0
Saudi Arabia
State/province [72] 0 0
Riyadh Province
Country [73] 0 0
Saudi Arabia
State/province [73] 0 0
Riyadh
Country [74] 0 0
Serbia
State/province [74] 0 0
Belgrade
Country [75] 0 0
Singapore
State/province [75] 0 0
Central
Country [76] 0 0
Spain
State/province [76] 0 0
Badajoz
Country [77] 0 0
Spain
State/province [77] 0 0
Barcelona
Country [78] 0 0
Spain
State/province [78] 0 0
Madrid
Country [79] 0 0
Spain
State/province [79] 0 0
Málaga
Country [80] 0 0
Spain
State/province [80] 0 0
Salamanca
Country [81] 0 0
Sweden
State/province [81] 0 0
Stockholm
Country [82] 0 0
Switzerland
State/province [82] 0 0
Basel
Country [83] 0 0
Taiwan
State/province [83] 0 0
Taichung
Country [84] 0 0
Thailand
State/province [84] 0 0
Central Thailand
Country [85] 0 0
United Arab Emirates
State/province [85] 0 0
Abu Dhabi
Country [86] 0 0
United Kingdom
State/province [86] 0 0
Soeast
Country [87] 0 0
United Kingdom
State/province [87] 0 0
South East England
Country [88] 0 0
United Kingdom
State/province [88] 0 0
Brighton

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Abbott Medical Devices
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The SyncAV Post-Market Trial is a prospective, randomized, multi-center trial performed to
determine if cardiac resynchronization therapy (CRT) devices programmed with SyncAV ON
improve long-term CRT response compared to devices programmed with conventional CRT through
evaluation of changes in left ventricular (LV) reverse remodeling.
Trial website
https://clinicaltrials.gov/ct2/show/NCT04100148
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Niraj Varma, MD
Address 0 0
The Cleveland Clinic
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Anuja A Kulkarni, MPH
Address 0 0
Country 0 0
Phone 0 0
408 845 8275
Fax 0 0
Email 0 0
[email protected]
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT04100148